We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+28.33%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$131M
AUM Growth
+$39.1M
Cap. Flow
+$20.1M
Cap. Flow %
15.4%
Top 10 Hldgs %
60.52%
Holding
43
New
14
Increased
9
Reduced
9
Closed
11

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$7.16M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.81M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$4.7M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$4.32M
5
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$4.23M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$6.15M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.62M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.24M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$3.41M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 86.37%
2 Financials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTS
26
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.48M 1.13%
+222,817
New +$1.5M
TPTX
27
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.46M 1.12%
+22,608
New +$1.3M
RCUS icon
28
Arcus Biosciences
RCUS
$3.64B
$1.26M 0.97%
+51,074
New +$1.38M
UBX
29
DELISTED
Unity Biotechnology
UBX
$1.04M 0.8%
+12,018
New +$891K
NXTC icon
30
NextCure
NXTC
$26.7M
$1.04M 0.8%
+4,038
New +$1.54M
RAPT
31
DELISTED
RAPT Therapeutics
RAPT
$1.01M 0.77%
+4,332
New +$670K
NCNA
32
NuCana
NCNA
$6.12M
$925K 0.71%
34
-3
-8% -$86.6K
BAX icon
33
Baxter International
BAX
$14.2B
– –
-75,737
Closed -$6.15M
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-54,676
Closed -$4.62M
QURE icon
35
uniQure
QURE
$3.22B
– –
-32,331
Closed -$1.53M
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.77B
– –
-15,016
Closed -$1.47M
TNDM icon
37
Tandem Diabetes Care
TNDM
$1.56B
– –
-32,292
Closed -$2.08M
XCUR icon
38
Exicure
XCUR
$8.54M
– –
-707
Closed -$157K
TECX
39
Tectonic Therapeutic
TECX
$606M
– –
-7,130
Closed -$1.33M
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
– –
-762,219
Closed -$1.13M
VAR
41
DELISTED
Varian Medical Systems, Inc.
VAR
– –
-17,484
Closed -$1.79M
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-72,712
Closed -$3.41M
IMMU
43
DELISTED
Immunomedics Inc
IMMU
– –
-92,147
Closed -$1.24M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Asymmetry Capital Management held 43 positions worth $131M, up 43% from $91.4M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Asymmetry Capital Management deployed $20.1M of net new capital in Q2 2020, opening 14 new positions and adding to 9 existing holdings. Its largest new stake was Sage Therapeutics: 197,249 shares worth $8.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $4.24M trimmed.

  • Asymmetry Capital Management's largest Q2 2020 buy was Sage Therapeutics: 197,249 shares worth $8.2M.
  • Asymmetry Capital Management added most to Global Blood Therapeutics, Inc. in Q2 2020, an estimated $5.81M increase.
  • Asymmetry Capital Management's biggest Q2 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $4.24M.
  • Asymmetry Capital Management fully exited Baxter International in Q2 2020, selling an estimated $6.15M.
  • Asymmetry Capital Management's ten largest holdings make up 61% of its $131M portfolio in Q2 2020.
  • Asymmetry Capital Management opened 14 new positions and closed 11 in Q2 2020.
  • Asymmetry Capital Management's portfolio value rose 43% quarter-over-quarter to $131M.

Based on Asymmetry Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.